about
Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometryMetabolic Enzymes Enjoying New Partnerships as RNA-Binding ProteinsThe diverse functions of GAPDH: views from different subcellular compartmentsRab2A is a pivotal switch protein that promotes either secretion or ER-associated degradation of (pro)insulin in insulin-secreting cells.Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis?Hind limb ischemia-reperfusion injury in diet-induced obese miceRole of NAD+ and mitochondrial sirtuins in cardiac and renal diseasesRenal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury.Pathophysiology of cisplatin-induced acute kidney injury.Identification of agents that reduce renal hypoxia-reoxygenation injury using cell-based screening: purine nucleosides are alternative energy sources in LLC-PK1 cells during hypoxiaARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion.Pathophysiological roles of peroxynitrite in circulatory shockTargeted deletion of p53 in the proximal tubule prevents ischemic renal injuryTIGAR regulates glycolysis in ischemic kidney proximal tubules.Renal nerves drive interstitial fibrogenesis in obstructive nephropathy.Two independent pathways of regulated necrosis mediate ischemia-reperfusion injuryPoly(ADP-ribose) polymerase regulates glycolytic activity in kidney proximal tubule epithelial cellsPoly-ADP-ribose-polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes.The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice.Nuclear GAPDH: changing the fate of Müller cells in diabetes.S100B impairs glycolysis via enhanced poly(ADP-ribosyl)ation of glyceraldehyde-3-phosphate dehydrogenase in rodent muscle cells.Mitochondrial poly(ADP-ribose) polymerase: The Wizard of Oz at work.Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.MicroRNA-489 Induction by Hypoxia-Inducible Factor-1 Protects against Ischemic Kidney Injury.Cyclophilin D gene ablation protects mice from ischemic renal injury.Intraperitoneal Administration of Oxygen/Ozone to Rats Reduces the Pancreatic Damage Induced by Streptozotocin.In situ lactate dehydrogenase activity: a novel renal cortical imaging biomarker of tubular injury?Endothelial Cell Metabolism.D-Glyceraldehyde-3-Phosphate Dehydrogenase Structure and Function.PARP inhibition attenuates histopathological lesion in ischemia/reperfusion renal mouse model after cold prolonged ischemia.5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats.Cellular glucose metabolism is essential for the reduction of cell-impermeable water-soluble tetrazolium (WST) dyesImmune mechanisms in the different phases of acute tubular necrosis
P2860
Q21245636-7641597B-44B7-46D9-87DF-A792ED2AC91CQ26777647-9C8380FE-1447-4579-ACBE-1DD020F382B4Q28291106-F986D6FB-56DE-4ECD-B627-808FB7F3D25AQ30844266-54EDACA5-0DA7-448A-9AFA-EE4D2AC3192AQ33851480-C6DB4D4F-0FAD-4C4C-B80F-E1C6FF46EBF0Q33895925-E43D8284-86B9-43BD-9E73-21A5488B0A02Q33899993-CE9299D3-B477-4370-9256-CDF6475B0116Q34062861-83D9AB43-C012-4BD8-826A-1FF93B0FF067Q34073302-2A5B889C-1843-452E-9BFA-81E0E2F3A7FBQ34078831-0E93B8CB-5140-4548-AE70-74D4E79B54D0Q34254806-BFD6B8C2-8998-4E72-983E-8D0196AAD56AQ34483863-B5CDFCEF-0101-4E37-B24E-F5B6A1CE68B8Q34568811-A09703E6-1B25-48A3-8618-F89D76F32EE4Q35086457-159AF5AF-F6FD-4B70-81DC-93419E336F85Q36574766-38F7744F-54EA-4AEE-9A9A-BC947F878607Q37031838-7156B7D6-57E4-4827-B405-E58C5F159426Q37053075-5CF202CB-D5C4-4864-B8CD-51B27660AB64Q37172217-3C6B2107-2A37-4BE6-8AE6-7A931A3ED06BQ37202759-58105D6B-91B9-4E6C-A8D4-0021586EFACDQ38094006-2408849D-3731-487D-A90D-49FC1BF68401Q38717429-C92D0C2A-D3DE-4E8D-B17A-13B0AD032562Q38768778-16526626-2A31-4B7C-964F-E649D8D82D6FQ39447083-A4EBD9D6-95A2-46BF-9FDD-EAEA8F556E40Q40974313-3DF06AFE-AE6D-4C9C-862F-0EF5EC275082Q45954261-87E5FC77-CEE1-4842-A2E4-09821ABC9461Q47556874-0D07F720-C75C-4E17-B7F8-3AB6B448EE42Q48341961-CE556F76-E36B-4933-A5EE-C157D08086BBQ49787990-6B6B5034-D227-4D19-806E-50E05CA005B9Q51107142-BABA4998-499A-4E15-BC93-92E7D49AFCFFQ54471607-E5AD3046-A417-4B78-936D-66528482A9F5Q55423967-7B1F4A75-3B93-420A-BD1C-D0585FBD71E9Q58758546-0770F797-4E83-482F-9F27-74129A9E5A5FQ58795413-048793D6-FC94-418A-B36B-D0F2257E884F
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
PARP-1 inhibits glycolysis in ischemic kidneys.
@en
PARP-1 inhibits glycolysis in ischemic kidneys.
@nl
type
label
PARP-1 inhibits glycolysis in ischemic kidneys.
@en
PARP-1 inhibits glycolysis in ischemic kidneys.
@nl
prefLabel
PARP-1 inhibits glycolysis in ischemic kidneys.
@en
PARP-1 inhibits glycolysis in ischemic kidneys.
@nl
P2860
P356
P1476
PARP-1 inhibits glycolysis in ischemic kidneys.
@en
P2093
Babu J Padanilam
Kishor Devalaraja-Narashimha
P2860
P304
P356
10.1681/ASN.2008030325
P577
2008-12-03T00:00:00Z